cardiology general-medicine
CHA2DS2-VASc Score (AF Stroke Risk)
Estimates annual stroke risk in non-valvular AF. Guides anticoagulation decision (OAC vs no treatment) per ESC/NICE guidelines.
Used in: Atrial Fibrillation
Score interpretation
Low risk (male) / Very low risk
→ Males: OAC not recommended. Reassess at each review.
Low-moderate risk
→ Males with score 1: OAC should be considered (DOAC preferred). Females: reassess at 2.
Moderate-high risk (OAC recommended)
→ OAC strongly recommended: apixaban, rivaroxaban, or edoxaban (DOAC preferred over warfarin). Assess bleeding risk (HAS-BLED).
Interpretation bands for the CHA2DS2-VASc. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- CHA₂DS₂-VASc Score · Atrial Fibrillation
- ORBIT Bleeding Risk Score for AF · Atrial Fibrillation
- CHA₂DS₂-VA Score for AF (2023) · Atrial Fibrillation
- CHADS-65 for Atrial Fibrillation · Atrial Fibrillation
- GARFIELD-AF Risk Score for Atrial Fibrillation · Atrial Fibrillation
- CHADS-65 Score for Atrial Fibrillation · Atrial Fibrillation
Drugs
- Edoxaban (AF Stroke Prevention / VTE) · Direct Factor Xa Inhibitor (DOAC)
- Warfarin · Anticoagulant
- Bivalirudin (PCI Anticoagulation) · Direct Thrombin Inhibitor / PCI
- Vernakalant · Atrial-selective antiarrhythmic
- Aspirin (Loading Dose) · Antiplatelet — ACS / Ischaemic Stroke
- Alteplase (tPA) · Thrombolytic — Ischaemic Stroke / Massive PE
Pathways
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.